Sr. Investor Relations Manager

## Who We Are: Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis\* and uterine fibroids\*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit [neurocrine.com](https://c212.net/c/link/?t=0&l=en&o=4450443-1&h=3502828688&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4252873-1%26h%3D4039787179%26u%3Dhttps%253A%252F%252Fwww.neurocrine.com%252F%26a%3Dneurocrine.com&a=neurocrine.com), and follow the company on [LinkedIn](https://c212.net/c/link/?t=0&l=en&o=4450443-1&h=884458364&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4252873-1%26h%3D928986078%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fneurocrine-biosciences%26a%3DLinkedIn&a=LinkedIn), [X](https://c212.net/c/link/?t=0&l=en&o=4450443-1&h=1730331693&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4252873-1%26h%3D3255611529%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fneurocrine%26a%3DX%2B%28formerly%2BTwitter%29&a=X), [Facebook](https://c212.net/c/link/?t=0&l=en&o=4450443-1&h=3526407131&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4252873-1%26h%3D1536396415%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FNeurocrine%26a%3DFacebook&a=Facebook) and [YouTube](https://www.youtube.com/@NeurocrineBiosciencesInc). (*\*in collaboration with AbbVie*) ## About the Role: Neurocrine Biosciences is seeking a highly motivated and strategic Senior Investor Relations Manager to support the execution of a best-in-class IR program. This role serves as a key partner to the Vice President of Investor Relations and collaborates closely with senior leadership, Finance, Legal, Commercial, and Corporate Communications to effectively communicate the company’s strategy, financial performance, and pipeline progress to the investment community. The Senior Manager operates with a high degree of autonomy and is responsible for leading key components of the IR strategy and driving execution of complex, high-impact initiatives. This individual will serve as a recognized functional expert in Investor Relations, shaping investor messaging, influencing engagement strategy, driving alignment across senior stakeholders and recommending enhancements to IR processes, tools and practices. \_ ## Your Contributions (include, but are not limited to): - Partner with the VP of Investor Relations to recommend, develop and execute IR strategy and priorities - Translate business performance, pipeline updates, and corporate strategy into clear, compelling investor narratives - Lead preparation of quarterly earnings materials, including press releases, scripts, presentations, and Q&A - Develop investor presentations, executive briefing materials, and content for investor events - Serve as a primary point of contact for select investors and sell-side analysts - Support and lead execution of investor events, including earnings calls, investor days, conferences, and non-deal roadshows - Ensure consistency, clarity, and strategic alignment across all external communications and disclosures - Partner cross-functionally with Finance, Legal, Commercial, R&D, a…